As the U.S. Department of Health and Human Services (HHS) is no longer distributing COVID-19 therapeutics, except to certain federal entities, we ask that all providers finalize their reporting data in the Health Partner Ordering Portal (HPOP). If your organization or site received COVID-19 therapeutics from HHS, please reconcile that therapeutics inventory in HPOP, to the extent possible,
by June 30. Federal entities that are receiving HHS-distributed oral antivirals must continue to report that inventory.
The reporting of HHS-procured therapeutics is required until all product received has been accounted for as administered, transferred, wasted, or returned. In some cases, such as for non-expired oral antivirals, this reconciliation may also include on-hand inventory that has not yet been dispensed. The therapeutics team recognizes 100% reporting may not be possible, and thus, is striving to reach at least a 95% reconciliation for each product HHS distributed.
Training and refresher steps for reporting are available in HPOP. Partners or sites that have not signed into their HPOP accounts in at least 45 days will need to reset their passwords. Central partners can set or change account users for providers sites, if needed. Sites can find the central partner’s contact information in HPOP under “Support Details/Partner Support Details”.
For providers who received HHS-distributed therapeutics:
- Ensure all reporting in HPOP is accurate.
- Ensure reporting of all products is updated to account for all delivered products as administered, transferred, wasted, returned or on-hand inventory
by June 30, 2024.
- Once all products are accounted for (at least 95%) and on-hand inventory is zero for each product, no additional reporting is required.
For all central partners (central awardees):
- Ensure all providers in your network that received HHS-distributed therapeutics finalize their reporting in HPOP
by June 30, 2024. Please note that for federal entities that continue to receive product, continued reporting is required.
- Across all providers in your network, ensure that all received product is accounted for as administered, transferred, wasted, returned or on-hand inventory.
- A new
Tiberius Awardee Management tool is available that can be used to track progress and reach out to provider sites as needed.
- Once you achieve the metric established in the
Tiberius Awardee Management Tool (at least 95% reconciliation) and current on-hand inventory is zero, no additional reporting for that product is required.
New Tiberius Tool:
We have a new tool available in Tiberius to provider a greater level of insight for our partners. The new tool, called the
Tiberius Awardee Management (TAM) portal, enables users to view metrics for product usage, current inventory level, reported wastage, and any resulting delta (unaccounted product at the awardee and provider level), and generate reports to capture all of this information. The functions and capabilities of this tool allow you to track reconciliation metrics for each therapeutic. Once the target reconciliation is achieved to the greatest extent possible, no additional reporting for that product is required.
New on the Treatments Locator:
We also are pleased to announce that the
Treatments Locator is now available in three languages:
English,
Spanish and
simplified Chinese. The locator displays approximately 60,000 pharmacies, clinics, and other locations with safe and effective COVID-19 outpatient medications. We welcome new locations.
Opting in takes just a few minutes using an HPOP account or through our
web form.
No commercially procured inventory numbers are needed. To remain on the locator, simply check in at least once every 60 days to note that the site has products in stock. More frequent updates keep the locator accurate to help patients and health care providers quickly find sites in their communities where the products are available.
For HPOP assistance, please
contact HPOP.support@hhs.gov. For other questions, please
reach out to COVID-19therapeutics@hhs.gov. Thank you for your continued partnership to ensure COVID-19 therapeutics accountability and availability.
